Life Sciences

  • November 25, 2020

    Monsanto, BASF Get $265M Dicamba Verdict Slashed To $75M

    A Missouri federal judge on Wednesday cut a punitive damages award that a Missouri farm won against Monsanto and BASF in a bellwether trial over claims the weedkiller dicamba ruined the farm's peach trees from $250 million to $60 million, ruling that the case involved only economic damages as opposed to physical harm.

  • November 25, 2020

    Zydus Insists Mitsubishi Doesn't Deserve Diabetes Patents

    Zydus Pharmaceuticals punctuated the six-day trial in its bid to bring generic diabetes drugs to market by filing a 100-page, post-trial brief doubling down on its claim that Mitsubishi Tanabe Pharma Corp. is engaging in "gamesmanship" to extend the life of one of three patents Zydus is accused of infringing.

  • November 25, 2020

    EU Regulatory Plan Targets Big Pharma Competition, Mergers

    The European Commission on Wednesday adopted a plan to develop a regulatory framework by 2022 to increase access to cheap generic drugs by cracking down on anti-competitive behaviors by pharmaceutical companies across the European Union.

  • November 25, 2020

    Appeals Court Says NJ Medical Pot Permit Scoring Is Flawed

    A New Jersey appellate panel said Wednesday there were serious problems with the way the state scored medical marijuana permit applications, sending the state's Department of Health back to reconsider applications submitted by rejected companies.

  • November 25, 2020

    US, Smith & Nephew Urge Justices To Overturn Arthrex

    The Federal Circuit misapplied clear U.S. Supreme Court precedent when finding that administrative patent judges weren't constitutionally appointed, the government and medical tech company Smith & Nephew said Wednesday in their opening salvos for the closely watched Arthrex case.

  • November 25, 2020

    SmileDirect Tries To Save Calif. Dental Board Suit At 9th Circ.

    SmileDirectClub has told the Ninth Circuit that a California federal court was wrong to find that what the company calls a harassment campaign by the state's dental board was instead a proper exercise of its regulatory authority.

  • November 25, 2020

    GAO Denies Protest Of Vaccine Research Contract

    The U.S. Government Accountability Office denied a bid protest from the global research firm Battelle Memorial Institute on Wednesday, the company's third such protest, because it found that the company's proposal had not been disparately evaluated by the Centers for Disease Control and Prevention.

  • November 25, 2020

    Goodwin Steers Mass Spectrometry Biz Eyeing $75M IPO

    Mass spectrometry company 908 Devices on Wednesday filed for an initial public offering guided by Goodwin Procter LLP that is preliminarily estimated to bring in about $75 million.

  • November 25, 2020

    Coronavirus Regulations: A State-By-State Week In Review

    Ahead of the long weekend, when Americans are most known for gathering and traveling, Thanksgiving-minded governors laid down more restrictions as COVID-19 cases continued surging over the past week.

  • November 25, 2020

    Sport Supplement Co., Owner Plead Guilty Over Steroids

    The U.S. Department of Justice on Wednesday announced that a North Carolina man and his sport supplement company pled guilty to a felony charge for illegally distributing steroids with the intent to defraud consumers and the U.S. Food and Drug Administration and agreed to forfeit $1.2 million.

  • November 25, 2020

    Suit Says 'Infant' Fever Drugs Are Same As 'Children' Drugs

    Parents who bought infant fever medication made by Prestige Consumer Healthcare Inc. are suing the company in California federal court, alleging in a proposed class action that the drugs are the same dosage and formula as the medication labeled for children, but at nearly double the price.

  • November 24, 2020

    Telehealth Platform Can't Oust Medical Pot Co., Judge Says

    An Illinois federal judge said on Monday that a cannabis telehealth service could not evict a medical marijuana business from its platform even if some of the company's practices were questionable, saying there was no material violation of the pair's agreement.

  • November 24, 2020

    Groups Sue Trump To Block New Drug Import Rule

    An organization representing top pharmaceutical research firms and two health care advocacy groups have sued the Trump administration in D.C. federal court to block a new federal policy allowing states, tribes, pharmacists and wholesalers to import certain prescription drugs from Canada without approval from drug manufacturers.

  • November 24, 2020

    Jury Awards $3.5M In Iowa Artificial Hip Trial

    An Iowa federal jury has awarded $3.5 million over a hip implant patient's claims that her Biomet M2a Magnum metal hip shedded microscopic particles and caused her to need revision surgery.

  • November 24, 2020

    Chancery Slams Gilead Stonewalling Over Records Demands

    Pointing to "overly aggressive" efforts by Gilead Sciences Inc. to shut down demands for records as part of stockholder investigations into potential company malfeasance over its AIDS drug, a Delaware vice chancellor has ordered the company to cooperate and authorized investors to seek shifting their legal fees to the company, saying Gilead's conduct "epitomizes a trend."

  • November 24, 2020

    No Discrimination Ban For Medical Pot Patients, Hospital Says

    A Pennsylvania hospital system urged a federal judge to throw out parts of a discrimination lawsuit filed by a former employee who was fired after testing positive for marijuana, saying state courts have rejected the idea that medical pot use is protected.

  • November 24, 2020

    HHS Says It's Working With Biden, Touts AstraZeneca Vaccine

    After appearing to hedge last week on the potential of a Joe Biden transition, the head of the U.S. Department of Health and Human Services said Tuesday that he's working with the president-elect's team and that the agency has high hopes for one of AstraZeneca's coronavirus vaccine candidates.

  • November 24, 2020

    Mallinckrodt Ch. 11 Pauses Express Scripts Antitrust Claims

    The court overseeing Mallinckrodt's bankruptcy proceedings has paused the city of Rockford, Illinois' separate antitrust case against Express Scripts for allegedly working with the troubled drug company to inflate prices of the hormone treatment Acthar.

  • November 24, 2020

    EEOC Nabs $310K Recovery In Race, Sex Harassment Suits

    Tegra Medical LLC agreed to pay $240,000 to end a U.S. Equal Employment Opportunity Commission suit claiming the company sat idly by as female workers faced lewd comments and unwanted advances, while the operator of Smashburger reached a $70,000 deal to wrap up a racial harassment case, the EEOC said Tuesday.

  • November 24, 2020

    Purdue Pleads Guilty In NJ To Criminal Opioid Conspiracy

    OxyContin maker Purdue Pharma LP's top officer entered guilty pleas Tuesday on behalf of the company to a three-count felony information detailing Purdue's long conspiracy to defeat federal opioid control programs and anti-kickback statutes, part of a wider $8.3 billion criminal and civil settlement with the U.S. Department of Justice.

  • November 24, 2020

    Biomet To Pay $21M In Hip Implant Defect Suit Verdict

    Biomet Inc. was hit with a $21 million judgment following a Missouri federal trial over whether its hip implants were defective and caused injuries to a woman who had her hips replaced in 2008, according to an order making the amount public on Tuesday.

  • November 24, 2020

    Pa. Retailers Accused Of Wrongly Charging Tax On Masks

    Several Pennsylvania retailers and big-box stores, including Walmart and Home Depot, wrongly charged sales tax on tax-exempt protective face masks and face coverings, claimed a proposed class action filed in a state court.

  • November 24, 2020

    USPTO Aims To End Tech Giants' PTAB Denials Challenge

    The U.S. Patent and Trademark Office has urged a California federal court to toss out a challenge by Apple and other tech titans over the Patent Trial and Appeal Board's practice of denying inter partes review in light of parallel infringement litigation.

  • November 24, 2020

    UK Antitrust Arm Mulling Bipolar Drug Co.'s Commitments

    The U.K.'s antitrust regulator is mulling over concessions pharmaceutical company Essential Pharma has said it will make after announcing it planned to withdraw a bipolar medication from the U.K. market and to use its dominant position to increase prices of that medication.

  • November 23, 2020

    Greenberg Traurig Clears Conflict Inquiry In $1B Fraud Case

    A Tennessee federal judge on Friday found that potential conflicts of interest do exist between several attorneys representing a pharmacy owner and pharmacies accused of a $1 billion insurance scheme, but waived the conflicts pertaining to a pair of Greenberg Traurig LLP lawyers.

Expert Analysis

  • Ethics Reminders As Employees Move To Or From Gov't

    Author Photo

    Many organizations are making plans for executives to go into government jobs, or for government officials to join a private sector team, but they must understand the many ethics rules that can put a damper on just how valuable the former employee or new hire can be, say Scott Thomas and Jennifer Carrier at Blank Rome.

  • NJ Cannabis Strides Highlight Nearby States' Need To Legalize

    Author Photo

    As New Jersey's ballot measure approving adult-use cannabis gives the state a strong head start in the race to legalization, neighboring states Pennsylvania, New York and Connecticut need to move quickly to follow suit or risk losing out on significant cannabis tax revenue, say attorneys at Saul Ewing.

  • Surveying Drug Pricing Reform: The Latest State Activity

    Author Photo

    Attorneys at Ropes & Gray explore four types of high-impact drug pricing initiatives at the state level — pricing transparency, pharmacy benefit manager controls, drug importation and value-based arrangements — examining how the current wave of reforms may affect drug companies' business operations.

  • Don't Fear IP-Antitrust 'Turducken' In Reverse-Payment Cases

    Author Photo

    Although some judges are apprehensive of a "turducken" analysis — a patent case stuffed inside a reverse-payment antitrust action — it is procedurally viable and may be a fair way to adjudicate the antitrust liability of generic companies settling Hatch-Waxman litigation, say attorneys at Katten.

  • How Joe Biden Will Change The FDA: Part 2

    Author Photo

    When the Biden administration takes control of the U.S. Food and Drug Administration, companies can expect to see increased attention to the safety of medical devices, the rigor of audits and inspections, and the concerns of consumer advocacy groups, say attorneys at Covington.

  • A Key To Helping Clients Make Better Decisions During Crisis

    Author Photo

    As the pandemic brings a variety of legal stresses for businesses, lawyers must understand the emotional dynamic of a crisis and the particular energy it produces to effectively fulfill their role as advisers, say Meredith Parfet and Aaron Solomon at Ravenyard Group.

  • How Joe Biden Will Change The FDA: Part 1

    Author Photo

    During the Trump administration, the U.S. Food and Drug Administration has tended to issue warning letters and other regulatory tools to secure voluntary corrective actions, but the Biden administration is likely to pursue more vigorous judicial enforcement, including through consent decrees and criminal referrals, say attorneys at Covington.

  • A Forgotten But Effective Tool Against Opioid Scams

    Author Photo

    With the pandemic contributing to rising rates of opioid and substance use disorders, prosecutors should consider the regrettably underused Eliminating Kickbacks in Recovery Act as a tool for targeting and shutting down body brokers and others in the treatment industry that place profits above patients, say Michael Adelberg and Matthew Rubin at Faegre Drinker, and Melissa Garrido at Boston University.

  • Ethics Considerations For Law Firms Implementing AI

    Author Photo

    Richard Finkelman and Yihua Astle at Berkeley Research Group discuss the ethical and bias concerns law firms must address when implementing artificial intelligence-powered applications for recruiting, conflict identification and client counseling.

  • When A Product Liability Case Can't Survive Outside An MDL

    Author Photo

    Baca v. Johnson & Johnson, a recent pelvic mesh lawsuit brought in Arizona federal court, is a perfect example of how some product liability cases that might be accepted in a multidistrict litigation contain deficiencies that cannot withstand scrutiny when tried individually, says Rachel Weil at Reed Smith.

  • How Federal Virus Liability Law Will Apply To Vaccine Claims

    Author Photo

    Three federal court decisions addressing the Public Readiness and Emergency Preparedness Act suggest that the law likely preempts state claims related to a COVID-19 vaccine, but is unlikely to cover the failure to administer the vaccine, says Nathan Adams at Holland & Knight.

  • Picking The Right Location And Tools For Virtual Courtrooms

    Author Photo

    Attorneys should consider the pros and cons of participating in virtual court proceedings from home versus their law firm offices, and whether they have the right audio, video and team communication tools for their particular setup, say attorneys at Arnold & Porter.

  • 5 Red Flags For Pandemic-Related Investment Scams

    Author Photo

    As the U.S. Securities and Exchange Commission clamps down on fraudsters seeking funding for pandemic-related products and services, several warning signs can help identify investment scams, says Alan Rosca at Goldman Scarlato.

  • Beware Atty Ethics Rules When Reporting COVID-19 Fraud

    Author Photo

    Attorneys considering blowing the whistle on False Claims Act violations by recipients of COVID-19 relief may face a number of ethical constraints on their ability to disclose client information and file qui tam actions, say Breon Peace and Jennifer Kennedy Park at Cleary.

  • Looking For Judicial Activists? Check The Footnotes

    Author Photo

    U.S. Supreme Court nominees typically face intense questioning over potential judicial activism, but a better way to gauge judges' activist tendencies may be to look at the footnotes in their opinions, say Christopher Collier at Hawkins Parnell and Michael Arndt at Rohan Law.

Want to publish in Law360?


Submit an idea
Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!